(Q53628573)

English

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. (English)

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

1 reference

based on heuristic

inferred from title

author name string

Roehrborn CG

1

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

Oesterling JE

2

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

Auerbach S

3

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

Kaplan SA

4

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

Lloyd LK

5

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

Milam DE

6

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

Padley RJ

7

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

language of work or name

0 references

publication date

1 February 1996

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

47

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

2

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

159-168

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

Natural history of prostatism: worry and embarrassment from urinary symptoms and health care-seeking behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Transurethral prostatectomy: practice aspects of the dominant operation in American urology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Contractile properties of human prostate adenomas and the development of infravesical obstruction.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Terazosin in the treatment of benign prostatic hyperplasia: the United States experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hard Measures of Subjective Outcomes: Validating Symptom Indexes in Urology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Watchful waiting vs immediate transurethral resection for symptomatic prostatism. The importance of patients' preferences

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Medical outcomes research and benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of terazosin for the treatment of symptomatic BPH

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980409-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(99)80409-9

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8607227

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53628573&oldid=1395314525"